Chelidonic acid
(Synonyms: 白屈菜酸) 目录号 : GC31886
A pyran with diverse biological activities
Cas No.:99-32-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Chelidonic acid is a pyran that has been found in C. majus and has diverse biological activities.1,2,3 It inhibits rat brain glutamate decarboxylase (Ki = 1.2 μM).2 Chelidonic acid (20 mg/kg per day) reduces serum IL-6 and TNF-α levels, colonic COX-2 and prostaglandin E2 levels, and the disease activity index score in a mouse model of ulcerative colitis induced by dextran sulfate sodium .1 It inhibits ovalbumin challenge-induced decreases in spleen IFN-γ levels and increases in serum, spleen, and nasal mucosa IgE levels, spleen IL-4 levels, and nasal mucosa eosinophil and mast cell infiltration in a mouse model of ovalbumin-sensitized allergic rhinitis when administered at a dose of 2 mg/kg.3
1.Kim, D.-S., Kim, S.-J., Kim, M.-C., et al.The therapeutic effect of chelidonic acid on ulcerative colitisBiol. Pharm. Bull.35(5)666-671(2012) 2.Porter, T.G., and Martin, C.L.Chelidonic acid and other conformationally restricted substrate analogues as inhibitors of rat brain glutamate decarboxylaseBiochem. Pharmacol.34(23)4145-4150(1985) 3.Oh, H.-A., Kim, H.-M., and Jeong, H.-J.Beneficial effects of chelidonic acid on a model of allergic rhinitisInt. Immunopharmacol.11(1)39-45(2011)
| Cas No. | 99-32-1 | SDF | |
| 别名 | 白屈菜酸 | ||
| Canonical SMILES | O=C(C1=CC(C=C(C(O)=O)O1)=O)O | ||
| 分子式 | C7H4O6 | 分子量 | 184.1 |
| 溶解度 | DMSO: 25 mg/mL (135.80 mM); Water: 2.5 mg/mL (13.58 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.4318 mL | 27.1592 mL | 54.3183 mL |
| 5 mM | 1.0864 mL | 5.4318 mL | 10.8637 mL |
| 10 mM | 0.5432 mL | 2.7159 mL | 5.4318 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Chelidonic acid evokes antidepressant-like effect through the up-regulation of BDNF in forced swimming test
Depression is usually accompanied by neuro-inflammatory reactions. Chelidonic acid, in particular, has shown anti-inflammatory effects. The objective of this study was to evaluate the anti-depressant effects of chelidonic acid and to discuss the potential mechanisms of a forced swimming test. Chelidonic acid was administered orally once a day for 14 days. On the 14th day, chelidonic acid resulted in a significant decrease in immobility time during the forced swimming test without alteration of locomotor activity, in an open field test. Chelidonic acid also increased the number of nissl bodies in the hippocampus. Brain-derived neurotrophic factor expression and extracellular signal-regulated protein kinase phosphorylation in the hippocampus were up-regulated by the administration of chelidonic acid. Chelidonic acid administration significantly increased the mRNA expression of hippocampal estrogen receptor-汕. The levels of hippocampal interleukin (IL)-1汕, IL-6, and tumor necrosis factor-汐 were effectively attenuated by the administration of chelidonic acid. In addition, chelidonic acid significantly increased the levels of 5-hydroxytryptamine (serotonin), dopamine, and norepinephrine compared with those levels for the mice that were administered distilled water in the hippocampus. These results suggest that chelidonic acid might serve as a new therapeutic strategy for the regulation of depression associated with inflammation.
Chelidonic Acid and Its Derivatives from Saussurea Controversa: Isolation, Structural Elucidation and Influence on the Osteogenic Differentiation of Multipotent Mesenchymal Stromal Cells In Vitro
4-oxo-4H-pyran-2.6-dicarboxylic acid (chelidonic acid, ChA) in the native state and in the complex with calcium [Ca(ChA)(H2O)3], named saucalchelin (CaChA), was isolated from the extract of Saussurea controversa leaves for the first time for the Asteraceae family. The structure of ChA was determined by NMR, MS and confirmed by X-ray analysis of its monomethyl ester, and CaChA was described by IR, ICP-MS, CHN analysis. The yield of ChA and CaChA was 45 mg/g and 70 mg/g of extract, respectively. The osteogenic activity of ChA, n-monobutyl ester of chelidonic acid, and CaChA has been studied in vitro in a 21-day culture of human adipose-derived multipotent mesenchymal stromal cells (hAMMSCs) in a standard nutrient medium without osteogenic supplements. CaChA significantly stimulated the growth of cell mass and differentiation of hAMMSCs into osteoblasts with subsequent mineralization of the culture and it may be a promising substance for accelerating bone tissue regeneration and engineering.
Chelidonic acid and other conformationally restricted substrate analogues as inhibitors of rat brain glutamate decarboxylase
Twenty conformationally restricted analogues of glutamate including benzoic acids, hydroxy-benzoic acids, pyridine dicarboxylic acids, and pyran dicarboxylic acids were tested as inhibitors of glutamate decarboxylase from rat brain. Chelidonic acid, 2,6-pyridine dicarboxylic acid, chelidamic acid, gallic acid, and 3,4-dihydroxybenzoic acid were the most potent inhibitors of the enzyme, and generally the aromatic analogues were much more potent inhibitors than their aliphatic counterparts. An intercarboxylate distance of 0.75 nm appears optimal for substrate competition, indicating that glutamate binds to the active site in an extended conformation. At least one carboxyl group can be replaced by a phenolic hydroxyl without greatly affecting inhibition. The degree of inhibition was also influenced by the aromatic structure, particularly with respect to the atom bridging the dicarboxylate carbons. Kinetic analysis of the inhibition by chelidonic acid and chelidamic acid showed that these compounds were competitive with glutamate with Ki values of 1.2 and 33 microM respectively. Consistent with this result, chelidonic acid also inhibited the glutamate-dependent formation of apoenzyme. Chelidonic acid itself did not promote formation of apoenzyme and did not react with free pyridoxal-P. The effects of different classes of glutamate decarboxylase inhibitors are discussed in relation to the formation of apoenzyme and its reactivation by pyridoxal-P. As one of the most potent inhibitors of glutamate decarboxylase known, chelidonic acid may be of value in studies of the regulation of gamma-aminobutyric acid synthesis.
Effects of chelidonic acid, a secondary plant metabolite, on mast cell degranulation and adaptive immunity in rats
The present study evaluated the immunomodulatory effects of chelidonic acid, a secondary plant metabolite, with therapeutic potential in allergic disorders, in experimental animals. In mast cell degranulation studies, ovalbumin immunized and challenged rats, chelidonic acid (1, 3 and 10mg/kg, i.p.) dose relatedly prevented ovalbumin challenge induced mast cell degranulation by differing degrees when compared with vehicle treated group, and these effects were comparable with prednisolone (10mg/kg). A reduction in post-challenge mortality was also observed in all treated groups. Further, there were reductions in the blood eosinophil counts and serum IgE levels after chelidonic acid treatment. Chelidonic acid also inhibited histamine release from rat peritoneal mast cells (RPMC) in vitro, in a dose related manner. In tests for adaptive immunity, in rats immunized with sheep RBC, chelidonic acid differentially suppressed the (a) plaque forming cell (PFC) count in rat splenic cells, (b) anti-SRBC antibody titre and serum IgG levels and (c) increases in foot pad thickness in the DTH assay - all of which were comparable with prednisolone. These experimental results are discussed in light of the possible therapeutic potential of chelidonic acid in allergic disorders.
The therapeutic effect of chelidonic acid on ulcerative colitis
Chelidonic acid (CA), a constituent of Chelidonium majus L., has many pharmacological effects, including mild analgesic and antimicrobial effects. However, the effects of CA on intestinal inflammation and the molecular mechanisms responsible are poorly understood. The aim of this study was to investigate the protective effects of CA against dextran sulfate sodium (DSS)-induced ulcerative colitis (UC). Mice treated with DSS displayed obvious clinic signs, such as, body weight loss and a shortening of colon length, but the administration of CA attenuated both of these signs. Additionally, CA was found to regulate levels of interleukin-6 and tumor necrosis factor-汐 in serum. In colonic tissues, prostaglandin E(2) (PGE(2)) production levels and cyclooxygenase-2 (COX-2) and hypoxia induced factor-1汐 (HIF-1汐) expression levels were increased by DSS, but CA attenuated increases in COX-2 and HIF-1汐 levels. These results provide novel insights into the pharmacological actions of CA and its potential use for the treatment of intestinal inflammation.